Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640102 · ClinicalTrials.gov registry record
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
A clinical trial of Waldenstrom Macroglobulinemia, sponsored by BeiGene.
- Recruiting
- Registry status
- 111
- Enrollment target
- 8
- Study locations
NCT05640102 is a study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by BeiGene. The registered enrollment target is 111 participants, below the 470-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (76% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05640102, a study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Conditions Studied
Interventions
- DRUG Zanubrutinib
Study Locations (8)
California
- City of Hope National Medical Center - Duarte
- Los Angeles Cancer Network (Lacn) - Glendale
- Eisenhower Medical Center, Lucy Curci Cancer Center - Rancho Mirage
Alabama
- Clearview Cancer Institute - Huntsville
- South Alabama Medical Science Foundation Mitchell Cancer Institute - Mobile
Mississippi
- Hattiesburg Hematology and Oncology Clinic - Hattiesburg
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Other
- Pan American Oncology Trials, Llc - Rio Piedras
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05640102
The ClinicalTrials.gov registry entry for NCT05640102 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (76% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Zanubrutinib is the first listed.
NCT05640102 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Mississippi.
Frequently Asked Questions
What is clinical trial NCT05640102 about?
NCT05640102 is a clinical study titled "Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia". This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this regi...
What is the current status of trial NCT05640102?
This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2023-03-03. Estimated completion is 2027-12.
What conditions does trial NCT05640102 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05640102?
The interventions under investigation include: Zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT05640102?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640102 being conducted?
This trial has 8 study locations across Alabama, California, Mississippi, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RECRUITING
-
Study of SGR-1505 in Mature B-Cell Neoplasms
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.